YH 32367
Alternative Names: ABL-105; YH-32367; YH-32384Latest Information Update: 06 Jun 2025
At a glance
- Originator ABL Bio
- Developer Yuhan
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 25 Apr 2025 Adverse events, efficacy and pharmacokinetics data from a phase I/II trial in Solid tumours presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
- 05 Apr 2024 Pharmacodynamics and adverse events data from a preclinical trial in solid tumour presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 01 Sep 2022 Yuhan Corporation plans a phase I/II trial(late staged disease, Metastatic disease) for Solid tumours in South Korea (NCT05523947)